analyzing their clinical, laboratory, and radiological outcomes within one year of follow‑up. Materials and methods: This retrospective study examined 179 patients who underwent PSE to manage hyper‑ splenism secondary to cirrhosis. Patients were divided into 3 groups according to embolic agent used. Group 1 (gelatin sponge) included 65 patients, group 2 (embospheres) included 58 patients, and group 3 (PVA) included 56 patients. Clinical, laboratory, and radiological outcomes were compared between groups. Results: The technical success rate was 100% in all groups. Pain as a major complication was lower in the gelatin sponge group (20%) compared to the embosphere group (31%) and PVA group (32.3%). Major complications other than pain were found in 20.1%; 24.6% in gelatin sponge group, 15.5% in embosphere group and 19.6% in PVA group (p= 0.045). WBCs and platelet counts showed a signifcant increase after PSE in all groups. Entire splenic volume as measured by computed tomography after PSE showed no signifcant diference among the 3 groups; however, the volume of infarcted spleen was signifcantly lower in the gelatin sponge group compared to other two groups (p= 0.001). The splenic span was signifcantly reduced one‑year post‑procedure in three groups (p= 0.006), and it was signifcantly less in embosphere and PVA groups compared to gelatin sponge group (p < 0.05). Recurrent bleeding was higher in gelatin sponge group (p < 0.05). Conclusions: Permanent embolic materials achieved better laboratory and radiological outcomes than gelatin sponge particles in PSE of cirrhotic hypersplenism patients. However, permanent particles were associated with greater abdominal pain.